Conversations With Experts: Successful Management of the Patient on NERLYNX® Therapy for HER2+ Breast Cancer: PATIENT CASE REVIEWS

Overview of NERLYNX® (neratinib) Tablets NERLYNX is a once-daily, oral kinase inhibitor that is ap-proved for extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. The recommended dose is 240 mg taken daily as six 40 mg tablets with food continu-ously for 1 year.1 NERLYNX has been shown to reduce the risk of recurrence in HER2+ early breast cancer patients.

Click here to view the PDF: Successful_Management_of_the_patient_on_NERLYNX